Methods: In this retrospective study, a total of 364 patients (170 males, 194 females; mean age 60.8±8.4 years; range: 33 to 82 years) with clinical stage T1aN0M0 pulmonary adenocarcinoma who were treated between January 2011 and October 2015 were included. Medical records were analyzed and relevant clinical data and pathological results were recorded. Univariate and multivariate analyses were performed to identify the predictors of lymph node metastasis.
Results: Multivariate analysis demonstrated that groundglass opacity, high serum carcinoembryonic antigen concentrations (>5 ng/mL), and pathogenic type were the predictors of lymph node metastasis in T1a pulmonary adenocarcinoma. For solid nodules, tumor diameter, air bronchogram, and high serum carcinoembryonic antigen concentrations were the predictors of lymph node metastasis.
Conclusion: Lymph node metastasis cannot be found in patients with clinical stage T1aN0M0 pulmonary adenocarcinoma presenting as a pure ground-glass opacity or mixed tumor with solid component of diameter <5 mm. However, systematic lymphadenectomy is indicated in all patients with pure solid nodules and those with mixed nodules with solid component ≥5 mm diameter, particularly those with serum carcinoembryonic antigen concentrations higher than 5 ng/mL.
In the present study, we aimed to identify predictors of LNM in patients with clinical stage T1aN0M0 pulmonary adenocarcinoma.
Inclusion criteria were as follows: (i) clinical stage T1aN0M0 pulmonary adenocarcinoma without other pulmonary nodules; (ii) previous systematic lymphadenectomy; and (iii) previous pulmonary segments or pulmonary lobe excision.
Exclusion criteria were as follows: (i) CT scanning showing one or more lymph node larger than 1 cm in diameter which indicated metastasis; (ii) N0 adenocarcinomas as assessed by mediastinoscopy; (iii) recent auxiliary chemotherapy or radiotherapy; and (iv) history of other malignant diseases.
All study patients underwent enhanced CT chest scanning and most patients with nodules <2 cm in diameter also underwent 2 mm high-resolution thin-layer CT scanning. Other routine preoperative investigations included the assessment of heart and lung function, brain CT or magnetic resonance imaging, bone scan, and abdominal CT or ultrasound. Based on the results of thin-layer CT examinations, the patients were assessed as having pure GGO lesions, mixed GGO lesions or solid nodules. The mixed GGO lesions were further subdivided as GGOs with a minimal solid content (solid content less than 5 mm diameter on imaging studies) and those with a marked solid content (solid content ≥5 mm diameter on imaging studies). In addition, GGO was defined as a slight uniform increase in density which was insufficient to obscure the pulmonary blood vessels. Pure solid nodules were defined as having totally solid content with a ground-glass component. Based on their CT scan findings, 364 patients (170 males, 194 females; mean age 60.8±8.4 years; range 33 to 82 years) were classified as having stage T1aN0M0. Lymph nodes with short axis larger than 1 cm were considered to denote presence of LNM.
All patients underwent lobectomy or segmentectomy, and the procedure depending on the surgeons preference, as there is still no consensus on which of these procedures is optimal. In general, segmentectomy was preferred for pure GGO lesions and lobectomy for mixed GGO and pure solid lesions.
Variables including age, gender, smoking history, relevant symptoms (i.e., cough, bloody phlegm, fever, chest pain or discomfort), tumor diameter, GGO status (GGO, mixed GGO and solid nodule), pleural involvement, air bronchogram, and serum carcinoembryonic antigen (CEA) concentrations were analyzed. The relationship between these variables and postoperative LNM status was assessed.
Statistical analysis
Statistical analysis was performed using the IBM
SPSS version 2.0 software (IBM Corp., Armonk, NY,
USA). The Students t-test and Fishers exact test were
used to assess the results of univariate and multivariate
analysis. Logistic regression analysis was used to
carry out multivariate analysis. A p value of <0.05 was
considered statistically significant.
In the pathological examination, of 364 patients, 15 (4.1%) and nine (2.5%) were found to have Stage N1 and N2 disease, respectively. Eight of nine patients with Stage N2 disease had also metastases in Stage N1 lymph nodes, while t he remaining patients (11.1%) had saltatory LNM. Univariate analysis revealed a relationship between the LNM, and appearance of nodule on CT scans, serum CEA concentrations, and pathological type (Table 1).
All tumors classified as pure GGO or GGO lesions with a minimal solid content (<5 mm diameter) were found to have Stage N0 disease. Pathological examination revealed that 22 of 56 patients (39.3%) with pure solid nodules had LNM (14 Stage N1 and eight N2); however, only three of the 172 patients (1.7%) with nodules with solid content diameter ≥5 mm were found to have LNM (two Stage N1 a nd o ne N2). The relationships between the GGO status, surgical procedure, LNM, and pathological tumor type are shown in Table 2. Standard pulmonary lobectomy was performed in 237 patients (65.1%) and 10 of whom were found to have stage N1 a nd f our N 2 diseases. Segmentectomy was performed in 127 patients (34.8%), six of whom had Stage N1 and four N2 diseases. A total of 38 (11.2%) patients without LNM had atypical adenomatous hyperplasia (AAH), 100 patients (29.5%) had an adenocarcinoma in situ (AIS), and 168 patients (49.6%) had a minimally invasive adenocarcinoma (MIA).
Pathological examination of the resected specimens of 136 patients with pure GGO tumors revealed that 90 (66.2%) were AIS, 38 (28.0%) were AAH, and eight (5.8%) were MIA. Of 172 patients with mixed GGO tumors, 158 (91.9%) were MIA, while the remaining 14 (8.1%) were IA. Of 56 patients with pure solid tumors, 54 (96.4%) had an invasive adenocarcinoma (IA), while remaining two had a mucinous adenocarcinoma.
Multivariate analysis showed that the GGO status, pathological type, and serum CEA concentrations were statistically significant predictors of LNM (p<0.05, Table 3).
In addition, multivariate analysis revealed that air bronchogram, tumor diameter, and high serum CEA concentrations were significant predictors of LNM (p<0.05, Table 4).
The ability to confidently predict LNM can result in safe avoidance of systematic lymphadenectomy in some patients. Several studies have already shown that systematic mediastinal lymphadenectomy is not essential.[3,6] However, there are two important differences between the aforementioned studies and the present study: first, our sample size was the largest thus far reported for this category of lung cancer; and second, our study incorporated the new pathological subtypes and new pulmonary adenocarcinoma staging of 2011.[8,9]
Previous studies also showed that clinical stage T1a lung cancer was not accompanied by mediastinal LNM.[4] However, in the current study, we identified LNM in 24 patients (6.6%) with clinical stage T1a pulmonary adenocarcinomas. Therefore, we believe that these patients require systematic lymph dissection.
In the present study, we also identified predictors of LNM in patients with clinical stage T1a lung adenocarcinomas that have not previously been reported. Hattori et al.[10] reported that tumor diameter, pure solid CT appearance, pleural involvement, air bronchogram, high CEA concentrations (>5 ng/mL), and positron emission tomography (PET) with maximum standard intake value (SUVmax value >5) were the main risk factors for LNM.
In our study, univariate and multivariate analysis revealed that the GGO status, high serum CEA concentrations (>5 ng/mL), and pathological type were the main predictors of LNM. As the GGO status can predict LNM more accurately than the tumor diameter,[11] we believe decisions on whether to perform mediastinal lymphadenectomy should not be based purely on the tumor size.
In addition, we also found that, of 136 patients with GGO tumors, 90 with AIS and eight with MIA had no LNM. Among 172 patients with mixed GGO tumors (158 with MIA and 14 with IA), two had LNM. Of 56 patients with pure solid nodules, 54 (96.5%) were IA and two (3.5%) were MIA, while 21 of these patients (37.5%) had LNM.
We, therefore, believe that all patients with nodules with a solid content of >5 mm in diameter or pure solid nodules should undergo systematic lymphadenectomy. Consistent with the current findings, Hattori et al.[10] also reported that solid nodules had a high-risk of lymph node involvement. In addition, Russell et al.[9] showed a relationship between Stage I-III lung adenocarcinoma subtypes and clinical characteristics and found that none of the patients with AIS, MIA, lepidicpredominant adenocarcinomas, or invasive mucinous adenocarcinomas had LNM, which is consistent with our findings. Additionally, we found that none of the patients with AAH, AIS or MIA had LNM, indicating that histological classification of clinical stage IA pulmonary adenocarcinomas can enable avoidance of systematic lymphadenectomy in a large proportion of patients. In the current study, Stage T1a pulmonary adenocarcinomas presenting as pure solid nodules on thin-layer CT had a high incidence of LNM. Multivariate analysis also showed that tumor diameter, high serum CEA concentrations, and pathological type were the main predictors of LNM. Based on these findings, we believe that patients with pure solid nodules must undergo systematic lymphadenectomy.
Limitations of the current study include its retrospective nature and lack of uniform PET scanning. Therefore, the relationship between the GGO status and lung adenocarcinoma subtypes requires further verification. We, hence, plan to perform a prospective, randomized-controlled study to confirm the present findings.
In conclusion, patients with clinical stage T1aN0M0 lung adenocarcinoma which has a solid content of <5 mm in diameter or pure ground-glass opacity on imaging studies do not require lymphadenectomy. However, systematic lymphadenectomy is indicated in patients with pure solid nodules or a solid content of ≥5 mm in diameter, particularly those whose serum carcinoembryonic antigen concentration is higher than 5 ng/mL.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research
and/or authorship of this article.
1) Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H,
Nagai K, et al. Tsuboi M, Shibata T, Fukuda H, Kato H;
Japan Lung Cancer Surgical Study Group (JCOG LCSSG).
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in
peripheral clinical IA lung cancer (Japan Clinical Oncology
Group 0201). J Thorac Oncol 2011;6:751-6.
2) Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya
R. Early peripheral lung cancer: prognostic significance of
ground glass opacity on thin-section computed tomographic
scan. Ann Thorac Surg 2002;74:1635-9.
3) Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy
versus limited resection for T1 N0 non-small cell lung
cancer. Lung Cancer Study Group. Ann Thorac Surg
1995;60:615-22.
4) Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis
of positron emission tomographic and computed tomographic
imaging in detecting mediastinal lymph node metastases in
nonsmall cell lung cancer. Ann Thorac Surg 2005;79:375-82.
5) Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura
H. Radiologic classification of small adenocarcinoma of the
lung: radiologic-pathologic correlation and its prognostic
impact. Ann Thorac Surg 2006;81:413-9.
6) Watanabe S, Oda M, Go T, Tsunezuka Y, Ohta Y, Watanabe
Y, Watanabe G. Should mediastinal nodal dissection be
routinely undertaken in patients with peripheral small-sized
(2 cm or less) lung cancer? Retrospective analysis of 225 patients. Eur J Cardiothorac Surg 2001;20:1007-11.
7) Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer
staging system. Chest 2009;136:260-71.
8) Travis WD, Brambilla E, Noguchi M, Nicholson AG,
Geisinger KR, Yatabe Y, et al. International association
for the study of lung cancer/american thoracic society/
european respiratory society international multidisciplinary
classification of lung adenocarcinoma. J Thorac Oncol
2011;6:244-85.
9) Russell PA, Wainer Z, Wright GM, Daniels M, Conron
M, Williams RA. Does lung adenocarcinoma subtype
predict patient survival?: A clinicopathologic study based
on the new International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory
Society international multidisciplinary lung adenocarcinoma
classification. J Thorac Oncol 2011;6:1496-504.